Exclusive Summary

• Core originator patents have expired in numerous countries, opening a golden prime window for distributors to launch early generics and capture significant market share.
• Targets an immense global population of over 537 million diabetic adults, critically addressing the 30-40% of patients suffering from Diabetic Kidney Disease (DKD).
• Strongly endorsed by global tier-one guidelines (ADA, KDIGO) as a preferred first-line therapy for cardio-renal protection, ensuring sustained and rigid clinical demand.
• Features a much less crowded competitive landscape compared to red-ocean products like Dapagliflozin, ensuring healthier margins for local distributors with its full 0.1g and 0.3g dosage line.
• Backed by highly cost-effective Chinese supply chains with ready CTD dossiers, guaranteeing strong price advantages and rapid overseas regulatory approvals.